Form 13-F position report

CUE BIOPHARMA INC

Reported by Point72 Asia Singapore Pte Ltd

CUE CUSIP 22978P106 Manager CIK 0001666791

Reported 27,764 shares, up 3,666 (15.2%) from the prior quarter.

Reported value 65.9%; share count 15.2% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q4 2024
Shares 27,764 Quarter-end amount reported
Reported value $30,263 Fair value at quarter end
Consecutive quarters held 3 Through Q4 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2024-06-30 65753
2024-09-30 18247
2024-12-31 30263
2025-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

4 quarters
Quarterly reported position history for CUE BIOPHARMA INC held by Point72 Asia Singapore Pte Ltd.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2025 Reduced 0 -27,764 (-100.0%) 0 $0 2025-05-15
Q4 2024 Added 27,764 +3,666 (15.2%) < 0.01% $30,263 2025-02-14
Q3 2024 Reduced 24,098 -28,929 (-54.6%) < 0.01% $18,247 2024-11-14
Q2 2024 New 53,027 +53,027 (0.0%) 0.01% $65,753 2024-08-14

Who else reported the position

61 managers reported CUE BIOPHARMA INC for Q4 2024.

Managers reporting CUE BIOPHARMA INC in Q4 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Bleichroeder LP Unchanged 4,997,240 0 1.37% $5,446,992 21 qtrs
VANGUARD GROUP INC Added 2,056,176 +24,755 < 0.01% $2,241,232 28 qtrs
BlackRock Inc Added 638,952 +67,977 < 0.01% $696,458 2 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 631,281 +122,454 < 0.01% $688,251 28 qtrs
Robertson Stephens Wealth Management LLC Unchanged 478,500 0 0.02% $521,565 18 qtrs
Sigma Planning Corp Added 447,175 +45,850 0.02% $487,421 24 qtrs
Good Life Advisors LLC Unchanged 400,000 0 0.03% $436,000 11 qtrs
Bank of America Corporation Added 324,315 +85,113 < 0.01% $353,503 28 qtrs
ADVISORY RESEARCH INC Unchanged 257,225 0 0.05% $280,375 16 qtrs
STIFEL FINANCIAL CORP Added 211,361 +17,139 < 0.01% $230,383 23 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2024
Filed
February 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
27,764
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.